Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Fabiola Giudici(University of Padua), Lajos Pusztai(Yale University), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rachel Schiff(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), PierFranco Conte(University of Padua), Sergio Venturini(University of Turin), Benedetta Conte(Ospedale Policlinico San Martino), Mario Giuliano(Regione Campania), Carla Rognoni(Bocconi University), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Mothaffar F. Rimawi(Baylor College of Medicine), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Aleix Prat(Hospital Clínic de Barcelona), Mariavittoria Locci, Angelo Di Leo(Hospital of Prato), Fabio Puglisi(University of Udine)
Cited by 35
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k